Monitor for further 13G amendments or a 13D conversion if Ikarian Capital continues reducing. The sub-5% position reduces the likelihood of activist pressure, but the ongoing reduction suggests waning conviction.
Price Chart
Executive Summary
Ikarian Capital, LLC filed an amended Schedule 13G disclosing a 4.4% passive stake in Quoin Pharmaceuticals Ltd. as of September 30, 2026, holding 211,538 American Depositary Shares. This is a decrease from prior filings where Ikarian Capital held a larger position, and the stake now sits below the 5% threshold based on 4,804,161 ADS outstanding. The filing confirms the position is passive with no activist intent.
Key Financial Metrics
Key Facts
- Ikarian Capital reports 211,538 ADS (4.4% of shares outstanding) as of September 30, 2026
- Stake is below the 5% threshold based on 4,804,161 ADS outstanding as of September 16, 2026
- Filing is an amendment to a prior Schedule 13G, indicating a reduction from a previously larger position
- Filer certifies passive intent under Rule 13d-1(b) — no activist plans
- Neil Shahrestani is the ultimate controlling person of Ikarian Capital
Financial Impact
Ikarian Capital reduced its stake in QNRX to 4.4% from a prior higher level, now below the 5% reporting threshold. The exact prior stake size is not stated in this filing.
Risk Factors
- Continued insider or institutional selling pressure
- Low liquidity micro-cap stock — any selling could have outsized price impact
- No stated catalyst for the stake reduction
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001778253-26-000004 |
| Document: 0001778253-26-000004-index.html | 0001778253-26-000004 |
| Document: 0001778253-26-000004.txt | 0001778253-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $4.04 | awaiting T+5 | — | $4.01 (−0.74%) |
Oct 19, 2026 7d ago | ANALYST-UPGRADE | $3.98 $4.01 | ▲ +0.75% | ▲ +0.90% | $4.01 (+0.75%) |
Oct 14, 2026 12d ago | 8-K | $4.10 $3.99 | ▼ −2.68% | ▼ −3.14% | $4.01 (−2.20%) |
Oct 12, 2026 14d ago | ANALYST-UPGRADE | $4.36 $3.98 | ▼ −8.72% | ▼ −6.81% | $4.01 (−8.03%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.55 $4.03 | ▲ +11.43% | ▲ +11.15% | $4.01 (+11.87%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.36 | ▼ −4.28% | ▼ −4.70% | $4.01 (−11.96%) |
Sep 28, 2026 28d ago | EFFECT | $5.26 $4.56 | ▲ +13.40% | ▲ +14.61% | $4.01 (+23.76%) |
Sep 22, 2026 4w ago | Press Release | $7.01 $4.88 | ▼ −30.39% | ▼ −29.20% | $4.01 (−42.80%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $5.26 | ▲ +23.77% | ▲ +22.75% | $4.01 (+41.88%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $6.90 | ▲ +2.37% | ▲ +3.33% | $4.01 (−40.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers